Contact Us on telegram or WhatsApp +917887449821 +919168783773 +91 9529672584 +91 7499402610 Mail :- skyblueinternational033@gmail.com internationalskyblue@gmail.com Viwe our catalog :- https://wa.me/c/917499402610 Name Semaglutide Purity ≥98% (as tested by HPLC, High-Performance Liquid Chromatography) CAS Number 910463-68-2 Molecular Formula C₁₈₇H₂₉₁N₄₅O₅₉ Molecular Weight ~4113.58 g/mol Peptide Sequence Modified GLP-1 (7-37) analog with substitutions to enhance stability Form Lyophilized powder (freeze-dried) Content 3mg per vial Semaglutide is a medication originally developed for type 2 diabetes and obesity treatment. It's a GLP-1 receptor agonist, meaning it mimics the hormone GLP-1, which helps regulate blood sugar and appetite. Type 2 Diabetes Management Lowers blood sugar by increasing insulin release and reducing glucagon secretion. Helps patients achieve better glycemic control. Weight Loss (Obesity or Overweight with Comorbidities) Reduces appetite and slows gastric emptying. FDA-approved under the brand name Wegovy for chronic weight management. 💉 Semaglutide 3mg – Dosing Guide (Research and Clinical Context) ✅ Clinically Approved Dosing (Prescription Use) Under brand names like Ozempic (for diabetes) and Wegovy (for weight loss), the FDA-approved semaglutide dosing follows this gradual titration to minimize side effects: Week Dose (Subcutaneous Injection) Weeks 1–4 0.25 mg once weekly Weeks 5–8 0.5 mg once weekly Weeks 9–12 1.0 mg once weekly (maintenance or increase as needed) Weeks 13+ 1.7 mg – 2.4 mg weekly (Wegovy max) or up to 2.0 mg (Ozempic max) Route: Subcutaneous injection (abdomen, thigh, or upper arm) Frequency: Once per week, same day/time ⚠️ Important Notes Side Effects: Can include nausea, vomiting, diarrhea, abdominal pain, and risk of pancreatitis. Not for Type 1 Diabetes or Ketoacidosis. Only certain brands and dosages are approved for specific uses.

TIZARO TIRZEPATIDE 12.5mg BUY IN CANADA, SINGAPORE, AUSTRALIA, USA, EUROPE, UAE Contact Us on telegram or WhatsApp ‪ +917887449821‬ ‪ +919168783773‬ ‪ +919529672584‬ ‪ +917499402610 Mail :- skyblueinternational033@gmail.com internationalskyblue@gmail.com Viwe our catalog :- https://www.skyblueinternationals.com/ Tirzepatide is FDA-approved to improve blood sugar (glucose) control in adults with type 2 diabetes, as an adjunct to diet and exercise. It is a once-weekly injectable medication. It works as a dual GIP and GLP-1 receptor agonist, enhancing insulin secretion, reducing glucagon levels, and slowing gastric emptying. It helps lower HbA1c and postprandial glucose levels. Although initially approved for type 2 diabetes, tirzepatide is also being used and studied for weight loss, especially under the brand name Zepbound (approved by the FDA in 2023 for chronic weight management). It is prescribed for people who are: Obese (BMI ≥30), or Overweight (BMI ≥27) with at least one weight-related condition (e.g., hypertension, type 2 diabetes, dyslipidemia). It reduces appetite and calorie intake significantly. 12.5 mg is typically a step-up dose. Patients usually start at a lower dose (e.g., 2.5 mg or 5 mg) and gradually increase every 4 weeks to minimize gastrointestinal side effects. 12.5 mg may be a maintenance or transitional dose toward the maximum dose of 15 mg/week, depending on individual tolerance and treatment goals. Generic Name Tirzepatide Brand Names Mounjaro (for diabetes), Zepbound (for weight loss) Dose Strength 12.5 mg Dosage Form Prefilled pen (subcutaneous injection) Route of Administration Subcutaneous (SC) – once weekly Appearance Clear, colorless to slightly yellow solution TIRZEPATIDE 12.5mg AVAILABLE IN INDIA AT BEST PRICE. https://www.skyblueinternationals.com/ LOOKING FOR GENERIC MEDICINES ??? https://www.skyblueinternationals.com/ TIRZEPATIDE 12.5mg AT LOWEST PRICE TIRZEPATIDE 12.5mg IN STOCK TIRZEPATIDE 12.5mg SHIPPING WORLD WIDE

TIZARO TIRZEPATIDE 7.5mg BUY'S IN CANADA, SINGAPORE, AUSTRALIA, USA, EUROPE, UAE Contact Us on telegram or WhatsApp ‪ +917887449821‬ ‪ +919168783773‬ ‪ +919529672584‬ ‪ +917499402610 Mail :- skyblueinternational033@gmail.com internationalskyblue@gmail.com Viwe our catalog :- https://www.skyblueinternationals.com/ DISCRIBTION :- Type 2 Diabetes Mellitus (T2DM) Helps lower blood sugar (HbA1c) effectively Improves insulin sensitivity and secretion Reduces fasting and post-meal glucose spikes ➡️ Often used when 5 mg dose is tolerated well but greater glycemic control is needed. Weight Loss / Obesity Treatment Used for chronic weight management in: Adults with BMI ≥30, or BMI ≥27 with obesity-related conditions (diabetes, hypertension, etc.) At 7.5 mg, patients often report: Stronger appetite suppression Increased fat loss Accelerated body weight reduction vs lower doses ❤️ Cardiometabolic Benefits (Research-based) Helps reduce: LDL cholesterol and triglycerides Blood pressure Systemic inflammation (CRP) 7.5 mg Once weekly (SC injection) Injection sites Abdomen, thigh, upper arm Titration path 2.5 mg → 5 mg → 7.5 mg Max approved dose Up to 15 mg (in some proto How Tizaro Works (Mechanism) GLP-1 action: Enhances insulin release, slows gastric emptying, reduces appetite GIP action: Increases fat metabolism, improves insulin response Together, this dual pathway provides: Superior glucose control Greater weight loss vs other GLP-1 drugs (like semaglutide) BUY FROM US WORLD WIDE SHIPPING WITH GOOD PACKAGING CONTACT US FOR BEST OFFERS & DEALS

Semaglutide 3mg USES Brand Name: Rybelsus Formulation: Oral tablet Dosing: Once daily, taken on an empty stomach with water Type 2 Diabetes Management (Primary Use) Initial dose: 3 mg is used as a starting dose to allow the body to adjust to the medication. It is not therapeutic on its own—patients are usually titrated to 7 mg or 14 mg for full glucose-lowering effect. Helps lower blood sugar (HbA1c) in adults with Type 2 diabetes. How It Works. Semaglutide is a GLP-1 receptor agonist, which: Stimulates insulin secretion (when glucose is high) Reduces glucagon secretion Slows gastric emptying Reduces appetite (mildly at this dose) DOSAGE :- Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly (2.1).  Administer once weekly at any time of day, with or without meals  If a dose is missed administer within 5 days of missed dose  Inject subcutaneously in the abdomen, thigh, or upper arm Indications & Uses Initial dose for Type 2 diabetes mellitus treatment (used for 30 days before titration to 7 mg or 14 mg) Helps lower blood glucose (HbA1c) Used in combination with diet and exercise Wegovy (semaglutide) for weight loss Wegovy (semaglutide) is used for weight loss and weight maintenance in patients 12 years and older with obesity Used for reducing major cardiovascular event risks (such as heart attack, stroke, or death) in adults with type 2 diabetes with known heart disease Injection is given 1 time a week under the skin of the stomach (belly), the thigh, or the upper arm, using an autoinjector (pen) This injection should be used in addition to a reduced-calorie diet and increased physical activity

Retatrutide (10mg) USA FAST DELIVERY Retatrutide (10mg : - Obesity and Overweight Management Retatrutide has demonstrated significant efficacy in promoting weight loss. In clinical trials, participants have achieved up to 24.2% weight loss over 48 weeks, outperforming existing treatments like semaglutide and tirzepatide. Form: Subcutaneous injection (once weekly) Dose Titration: To reduce side effects (especially GI issues), dosing typically starts low and increases over time. What Is Retatrutide Used For? Retatrutide is being developed to target multiple metabolic conditions, with its primary uses in obesity management, type 2 diabetes, and fatty liver disease. Retatrutide activates the GIP, GLP-1 and glucagon receptors that are involved with controlling hunger and satiety, allowing people to feel fuller after eating for longer. This helps to regulate blood sugar levels, leading to weight loss. Non-Alcoholic Fatty Liver Disease (NAFLD) Retatrutide has led to significant reductions in liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with reductions up to 82.4% observed in clinical trials. Target Population Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities (e.g., type 2 diabetes, hypertension) Adults with type 2 diabetes, especially those who need better weight and glucose control EXPORT FROM INDIA IN CHEAPEST PRICE. Retatrutide is an investigational drug still in clinical trials and has not yet been approved by the FDA for general use. However, based on Phase 2 clinical trials.